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A B S T R A C T
Background
Antiviral agents against herpes simplex virus are widely used in the treatment of idiopathic facial paralysis (Bell’s palsy), but their
effectiveness is uncertain. Significant morbidity can be associated with severe cases.
Objectives
This review addresses the effect of antiviral therapy on Bell’s palsy.
Search methods
We updated the search of the Cochrane Neuromuscular Disease Group Trials Register (December 2008), MEDLINE (from January
1966 to December 8 2008), EMBASE (from January 1980 to December 8 2008) and LILACS (from January 1982 to December
2008).
Selection criteria
Randomized trials of antivirals with and without corticosteroids versus control therapies for the treatment of Bell’s palsy.
Data collection and analysis
Twenty-three papers were selected for consideration.
Main results
Seven trials including 1987 participants met the inclusion criteria, adding five studies to the two in the previous review.
Incomplete recovery at one year. There was no significant benefit in the rate of incomplete recovery from antivirals compared with
placebo (n = 1886, RR 0.88, 95% CI 0.65 to 1.18). In meta-analyses with some unexplained heterogeneity, the outcome with antivirals
was significantly worse than with corticosteroids (n = 768, RR 2.82, 95% CI 1.09 to 7.32) and the outcome with antivirals plus
corticosteroids was significantly better than with placebo (n = 658, RR 0.56, 95% CI 0.41 to 0.76).
Motor synkinesis or crocodile tears at one year. In single trials, there was no significant difference in long term sequelae comparing
antivirals and corticosteroids with corticosteroids alone (n = 99, RR 0.39, 95% CI 0.14 to 1.07) or antivirals with corticosteroids (n =
101, RR 1.03, 95% CI 0.51 to 2.07).
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Adverse events.There was no significant difference in rates of adverse events between antivirals and placebo (n = 1544, RR 1.06, 95%
CI 0.81 to 1.38), between antivirals and corticosteroids (n = 667, RR 0.96, 95%CI 0.65 to 1.41) or between the antiviral-corticosteroid
combination and placebo (n = 658, RR 1.15, 95% CI 0.79 to 1.66).
Authors’ conclusions
High quality evidence showed no significant benefit from anti-herpes simplex antivirals compared with placebo in producing complete
recovery from Bell’s palsy. Moderate quality evidence showed that antivirals were significantly less likely than corticosteroids to produce
complete recovery.
P L A I N L A N G U A G E S U M M A R Y
Antiviral treatment for Bell’s palsy
Bell’s palsy is a disease of the facial nerve which causes one side of the face to be paralysed. Some studies have suggested that it is caused
by infection with the cold sore (herpes simplex) virus. If this is correct, antiviral drugs against herpes simplex would be likely to help
recovery. It has also been suggested that corticosteroids may help. The paralysis is usually temporary even when untreated, although
without treatment about one person in five is left with permanent facial disfigurement or pain.
This updated review provided high quality evidence that antivirals are no more effective than placebo (dummy) treatment in producing
complete recovery. On the other hand moderate quality evidence showed that antivirals were less effective than corticosteroids and that
combined antiviral-corticosteroid treatment were more effective than placebo. Taken together, these results suggest that corticosteroids
might be effective but this requires confirmation from the Cochrane review of corticosteroids which is being updated. There was no
evidence that antivirals produced significantly more or significantly fewer adverse events than dummy treatment.
As this analysis shows that antivirals against the cold sore virus are not significantly effective, other causes for Bell’s palsy than infection
by the cold sore virus now need to be considered.
B A C K G R O U N D
Bell’s palsy is an acute unilateral paralysis of the facial nerve first
described by the Scottish surgeon Sir Charles Bell (1774 to 1842)
(Petruzelli 1991). It affects 11 to 40 people per 100,000 in the
population per annum, most commonly in the age group 30 to
45 (Bateman 1992; Brandenberg 1993; Katusic 1986; Pietersen
1982; Pietersen 2002; Yanagihara 1988). The condition presents
disproportionately amongst pregnant women and people who
have diabetes, influenza, a cold, or some other upper respiratory ail-
ment. On average, every year a British general practitioner will see
one or two people who have developed the condition. A UK study
using the general practice research database (GPRD) showed that
36%of people were treatedwith oral corticosteroids and 19%were
referred to hospital (Rowlands 2002). Althoughmost recover well,
30% of people with Bell’s palsy have a poor recovery with continu-
ing facial disfigurement, psychological difficulties and sometimes
facial pain (though the presence and course of pain is unclear from
current knowledge) (Morgenlander 1990). The aetiology has yet
be established but genetic, vascular, infectious and immunological
causes have all been postulated (Adour 1996). Animal studies have
suggested the possibility that reactivation of herpes viruses may be
responsible for demyelination (Morgan 1995; Sugita 1995). Her-
pes simplex virus, has been implicated as a cause in several studies
(McCormick 1972; Murakami 1996; Stjernquist-Desatnik 2006;
Takasu 1992; Theil 2001). Infection with this virus is thought to
cause inflammation of the facial nerve. Treatment has commonly
been based on this hypothesis. Antiviral medication is supposed
to eradicate the infectious agent and corticosteroids to reduce the
swelling of the facial nerve.
The previous versions of the Cochrane reviews concerning the
treatment of Bell’s palsy examined the effectiveness of oral pred-
nisolone and aciclovir (Allen 2007; Salinas 2002). These found
that insufficient data exist to conclude that either or both therapies
are effective. Many of the studies mentioned in these reviews but
excluded from the analysis either failed to randomize participants
or, when correctly randomized, were erroneously interpreted in a
favourable light (May 1976; Wolf 1978). In addition, high dose
corticosteroid therapy has numerous potential side effects includ-
ing peptic ulceration hypertension and confusional states. Antivi-
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ral therapy is expensive and should be reserved for circumstances
where definite benefits are likely to be obtained. Previous recom-
mendations suggested that aciclovir needs to be started within 48
hours, although a study of viral replication in participants with
Bell’s palsy suggested that the window might be extended (Abiko
2002).
Since publication of the previous versions of theCochrane reviews,
large scale, randomized controlled trials of antivirals and corticos-
teroids have been published necessitating substantive updates of
the reviews.
O B J E C T I V E S
The objective of the review was to determine the effectiveness of
anti-herpes simplex antiviral treatments for Bell’s palsy. We se-
lected as outcome variables (i) recovery status measured by con-
ventional validated instruments and (ii) presence of motor synki-
nesis or crocodile tears. A third outcome variable, adverse effects
of treatment, was also collected. Other symptoms (pain, discom-
fort and embarrassment) have been reported as outcomes in some
trials but were not considered in this review.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We searched for all randomized or quasi-randomized (alternate or
other systematic allocation) controlled trials involving aciclovir,
valaciclovir or famciclovir alone or in combination with any other
therapy in the treatment of Bell’s palsy.
Types of participants
We considered all trials where participants were diagnosed with
unilateral facial paralysis of unknown cause, and who satisfied the
authors’ requirements for eligibility and inclusion.
Types of interventions
We considered all trials where treatment was undertaken with any
oral antiviral licensed for the treatment of herpes simplex infections
in immunocompetent participants. The list comprised aciclovir,
valaciclovir, a pro-drug of aciclovir and famciclovir, a prodrug
of penciclovir. We considered trials where participants received
antiviral therapy versus placebo or any other treatment.
Types of outcome measures
The outcome measures have been modified since the previous
review to take into account the heterogeneity of this group of
studies.
Where outcome measures were measured ’at six months’, this has
been replaced by ’at the end of the study’. Duration of studies
included in this review ranges from three months to 12 months:
this method allows maximum data inclusion.
Incomplete recovery has been altered to include the range of defi-
nitions used by the studies included to allow maximum data cap-
ture: as opposed to the previous definition of moderate dysfunc-
tion, the term now includes participants with a lack of full func-
tion. More participants will be classified as ’incomplete recovery’
by this definition.
’Adverse events attributable to antiviral treatment’ has been re-
placed with ’adverse events’: in studies where both agents are ad-
ministered it is difficult to assess which agent is causing the adverse
event. Similarly, even when only an antiviral is being prescribed, it
is difficult to know whether a specific event should be attributed
to the medication or another intercurrent cause. The level of de-
tailed analysis of adverse events in studies did not permit such a
judgement being made.
Primary outcomes
Incomplete recovery of facial function at the endof studymeasured
using a validated rating scale.
Secondary outcomes
1. Motor synkinesis or crocodile tears at the end of the study.
2. Complete facial paralysis at the end of the study.
3. Adverse events.
Search methods for identification of studies
In this updated review, we searched the Cochrane Neuromuscular
Disease Group Trials register (December 2008), MEDLINE (Jan-
uary 1966 to December 8 2008), EMBASE (January 1980 to De-
cember 8 2008) and LILACS (January 1982 to December 2008).
We also reviewed the bibliographies of the identified trials, con-
tacted trial authors and known experts in the field and contacted
relevant drug companies to identify additional published or un-
published data. For MEDLINE, EMBASE and LILACS database
search strategies please see Appendix 1, Appendix 2 and Appendix
3.
Data collection and analysis
All five authors scrutinised the search databases to determine pa-
pers for inclusion. At least two authors independently assessed
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each paper for relevance, eligibility and quality. There were no
disagreements about inclusion.
In the first version of this review four possible trials were identified
but only two qualified for inclusion. The number of references
retrieved from each source was not stated. A search at the update
in April 2003 generated 49 papers in EMBASE, 22 inMEDLINE
and 15 in LILACS but no new trials were identified. Our new
search in 2008 identified 68 papers in EMBASE, 26 inMEDLINE
and 3 in LILACS. From this search, 23 papers were selected for
review of the full text and five trials were subsequently included
in addition to those which were included in the previous version
of the review.
We considered each trial design and whether it was randomized,
method of randomization to treatment, dosage of all treatment
comparisons (amount, frequency, duration and route of admin-
istration), whether the trial was placebo-controlled, blinded (for
treatment administrator, patient and assessment of recovery status)
or unstated, and for definition of recovery status. All five authors
were given a selection of papers to read, review for quality and ex-
tract data from. Each trial was assessed by at least two authors. PL
completed the risk of bias table which was individually reviewed
by FS and FD. All five authors agreed data extraction. Two authors
(PL and FD) agreed input into Review Manager (RevMan, the
programme provided by the Cochrane Collaboration).
Three of the trial authors were contacted for additional informa-
tion and two responded with data. A previous review author was
contacted for updated information on other studies and a response
was received.
Assessment of bias was conducted by scoring studies using the risk
of bias methods described in the 2008 version of the Cochrane
Handbook.according to Cochrane methods.
We calculated a weighted treatment effect using theMantel-Haen-
szel method (Egger 2007). The random effects model was used
where there was marked heterogeneity between studies (Chi2 test,
P < 0.1, I2 > 50%). The fixed-effect model was used where het-
erogeneity was not detected with standard statistical methods.
When comparing studies which use differing symptom scores to
assess outcome, we used theHouse-Brackman scale when available
as this was themost widely used or had comparisons to other scales
available.
When assessing adverse events, the number of participants af-
fected, as opposed to the number of events was used to facilitate
data comparison.
As in previous editions of this review, the meta-analysis outcomes
have been reported for both studies which compare antivirals ei-
ther with or without corticosteroids to corticosteroids and those
studies which compare antivirals only to corticosteroids only. We
have conducted three comparisons: antivirals versus placebo (in-
cluding antivirals plus corticosteroids versus placebo plus corti-
costeroids and antivirals plus corticosteroids versus no treatment
plus corticosteroids), antivirals versus corticosteroids and antivi-
rals plus corticosteroids versus placebo.
Sensitivity analysis has been used to assess the effects of combining
trials with and without additional treatments in the analysis of
antivirals verus placebo and the impact of length of follow up on
the meta-analysis results.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Five randomized controlled trials with 1787 participants in total
were added to the previous version of this review which had two
trials and 200 participants. All five trials provided a comparison of
disease outcome after antiviral treatment with disease outcome af-
ter an otherwise identical treatment regimen lacking the antiviral
component. One thousand nine hundred and eighty-seven par-
ticipants were included in the seven included studies.
Engstrom (Engström 2008) recruited 829 participants to be
treated within 72 hours of onset and randomized by a com-
puterised mechanism in a two-stage process into four treatment
groups: valaciclovir with prednisolone or valaciclovir with placebo
or placebo with prednisolone or double placebo in a factorial de-
sign. The trial was blinded for administrator, patient and assess-
ment of recovery status until the end of follow-up. Participants
were assessed at onset, after two weeks (11 to 17 days), after one,
two, three, six and 12 months. Disease status was measured using
the House-Brackmann grading system and the Sunnybrook scale.
Recovery status was defined by a Sunnybrook score of 100 and
a House-Brackman grade of 1. Time to recovery was estimated.
Data analysis included an assessment of treatment interaction.
The study reported no effect on recovery time due to valaciclovir
(P = 0.76). Recovery rates at 12 months were 57.5% in the valaci-
clovir group compared with 57.3% in the placebo group (P =
1.00). For this review, we aggregated the antiviral plus corticos-
teroid with the antiviral plus placebo group and the corticosteroid
plus placebo with the double placebo group to achieve the most
powerful comparison for the effect of treatment with valaciclovir
on recovery rates at 12 months. We analysed these recovery rates
12 months after palsy onset from their results. With complete re-
covery defined as a Sunnybrook score of 100, 271 out of 413 re-
covered with valaciclovir compared with 266 out of 416 recovered
without valaciclovir, RR 1.03. With complete recovery defined as
a House-Brackmann grade of I, 297 out of 413 recovered with
valaciclovir compared with 293 out of 416 without valaciclovir,
RR 1.02.
Hato (Hato 2007) randomized 296 participants within seven days
of onset using sealed envelopes into two treatment groups: valaci-
clovir with prednisolone or placebo with prednisolone. Two hun-
dred and twenty-one participants were included in the final anal-
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ysis. The administrators were not blinded to the treatment alloca-
tionbut the participantswere blinded to treatment received.Those
assessing recovery status were not blinded to treatment. Partici-
pants’ disease severity was assessed using the Yanagihara scale and
were assessed as completely recovered if attaining a score greater
than 36. Participants were assessed at onset andmonthly thereafter
for six months or until completely recovered if recovery occurred
before six months.
The group reported significant benefit from treatment with antivi-
rals and corticosteroids compared to corticosteroids alone: recov-
ery in the group receiving valaciclovir and prednisolone was seen
in 110/114 and recovery in the placebo and prednisolone group
was seen in 96/107, RR 1.08 at six months after palsy onset.
Kawaguchi (Kawaguchi 2007) recruited 150 participants to be
treated within seven days of onset and randomized using sealed en-
velopes into two treatment groups: valaciclovir with prednisolone
or prednisolone alone. Thus we deduce that there was no blinding
for administrator or participant. Participants were assessed at onset
using both the Yanagihara 40-point scale and House-Brackmann
index. Recovery was measured using only the Yanagihara index
(36 or more). Recovery time in days was recorded. Follow up was
scheduled for one week, two weeks and one, two, three, four, five
and six months.
This trial reported no significant difference in recovery rate be-
tween the prednisolone group and the prednisolone-aciclovir
group at six months.
Sullivan (Sullivan 2007 ) recruited 551 participants to be treated
within 72 hours of onset and randomized by a dedicated remote
telephone-computerised mechanism in a two-stage process into
four treatment groups: aciclovir with prednisolone (AS) or aci-
clovir with placebo (AO) or placebo with prednisolone (OS) or
double placebo (OO) in a factorial design. The trial was blinded
for administrator, participant and assessment of recovery status
until the end of follow-up. Participants were assessed at onset, af-
ter three months, and if still unwell at three months, after nine
months. Recovery status was measured using the House-Brack-
mann scale with complete recovery defined by House-Brackmann
grade I. Data analysis included an assessment of treatment inter-
action.
Sullivan (Sullivan 2007) reported final outcomes on 496 com-
pleted participants at three months and nine months and shows
a beneficial effect of not receiving antivirals. The nine month re-
covery rates were 211 out of 247 in the aciclovir group compared
with 226 out of 249 among participants not receiving aciclovir,
RR 0.92.
Yeo (Yeo 2008) recruited 91 participants with Bell’s palsy who
were randomized to receive either aciclovir and prednisolone or
prednisolone alone. All participants also received physical therapy
and plasma volume expanders as adjuncts. The trial was double
blind and participants were followed up for six months or until
complete recovery. Recovery was assessed using the House-Brack-
mann scale and defined as a House-Brackmann score of 2 or less.
Yeo (Yeo 2008) reported outcomes for 91 participants at two and
six months. There was no significant difference in recovery be-
tween the two treatment groups. The six month recovery rate in
the antivirals and corticosteroids group was 44 out of 44 and in
the corticosteroids only group 40 out of 47, RR 1.17.
Details of other studies previously included in this review are given
below.
Adour (Adour 1996) recruited 119 participants of whom 99 were
included in the published analysis. The study was double-blind
and placebo-controlled. Participants were recruited within three
or less days since the onset of paralysis and received either aciclovir
andprednisolone or placebo andprednisolone.The study duration
was four months and participants were reviewed at two weeks,
two months and four months. This was a single centre study. The
Facial Paralysis Recovery Index (FPRI) was used to measure facial
function and the primary trial outcome was incomplete recovery
defined by a FPRI 7 or less.
This study reported significant benefit of treatment with aciclovir
plus corticosteroids compared with corticosteroids alone, RR 1.22
after four months.
De Diego (De Diego 1998) recruited 113 participants and in-
cluded 101 in the final analyses. Participants were randomly as-
signed treatment: blinding status was not clear. Evaluation was
carried out within 48 hours of the onset of symptoms and partic-
ipants received either aciclovir for 10 days or prednisolone for 16
days (reducing dose). Reviews were scheduled for one, three, six
and 12 weeks after initial contact with further contact if persistent
incomplete recovery was noted. The primary study outcome was
recovery as defined using the House-Brackmann and facial paral-
ysis recovery profile scales. Full recovery was defined as a House-
Brackman score of 2 or less or a Facial Paralysis Recovery Profile
(FPRP) of 8 or more. The final length of follow-up is not reported
but stated as ’until complete recovery or stabilization of the paral-
ysis’.
This study reported significant treatment benefit in the corticos-
teroids only group, RR 0.83.
We have changed the status of the Antunes (Antunes 2000) study
for this report from ’included’ to ’excluded’. The authors of the
previous edition of this review initially included it but found the
data to be incomplete and, despite attempting to contact the au-
thors, there was not sufficient information for the data to be use-
fully included in the analyses.
We have reassessed the inclusion of the two studies awaiting assess-
ment (P de Aquino 2001; Roy 2005). The author of the previous
version of this review, Dr. D. Allen, tried to contact the author
of the former paper for clarification of the data, but this has not
been forthcoming and so we have excluded this trial because of
a lack of adequate information. The latter study appeared as an
abstract in a journal supplement and has not, according to the
search strategies employed, been published as a full paper. Again,
this trial has been excluded due to a lack of adequate information.
A further study awaits classification (Inanli 2001).This was in-
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cluded in a recently published systematic review and meta-anal-
ysis (Goudakos 2009). We await translation and interpretation.
Updated status of this paper will be included in the next update
of the Cochrane Review.
Risk of bias in included studies
The risk of bias is summarised in Figure 1.
Figure 1. Risk of bias summary: review authors’ judgments about each risk of bias domain for each included
study.
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Sequence generation, allocation concealment and
blinding
Three studies (Adour 1996; Engström 2008; Sullivan 2007) were
randomized, double-blind and placebo-controlled tominimise the
effects of bias. Kawaguchi (Kawaguchi 2007) described a random-
ized study but states that the treatment was revealed to the clini-
cian and the absence of a placebo made treatment clear to the re-
cipient. The remaining two studies (De Diego 1998; Hato 2007)
all described randomization but not blinding or placebo use. Yeo
(Yeo 2008) stated that their study was randomized and double-
blind: this was not described within the text and so this study has
been graded as unclear for these attributes.
Incomplete outcome data
All studies, except Yeo (Yeo 2008) reported frequencies, and often
reasons, for failure to complete follow-up.
Most trials (Engström 2008; Kawaguchi 2007; De Diego 1998;
Sullivan 2007; Yeo 2008) reported a drop-out rate of 10% or less
except Adour 1996,16.8% and Hato 2007,19% .
Selective outcome reporting
All studies, except Adour 1996 reported all their intended primary
outcomes. Adour failed to report on audiometry and stapedial
reflex testing. Engström 2008 reported all primary outcomes and
stated that secondary outcomes will be reported in a later paper.
Other potential sources of bias
Diagnostic criteria
Six studies (De Diego 1998; Engström 2008; Hato 2007;
Kawaguchi 2007; Sullivan 2007; Yeo 2008) gave adequate infor-
mation. All studies explicitly mentioned a diagnosis of Bell’s palsy
and stated that other causes of facial palsy had been considered
and excluded. Two trials (Hato 2007; Kawaguchi 2007) retrospec-
tively excluded participants on the basis of positive serology for
herpes simplex (HSV) or varicella zoster (VZV) viruses. Two stud-
ies (Engström 2008; Sullivan 2007) mention referral to specialists
for diagnostic confirmation.
The remaining study Adour 1996 stated participants were diag-
nosed with Bell’s palsy but did not give any further information.
Outcome criteria
All studies used referenced facial function scoring systems to grade
recovery from facial paralysis. Adour (Adour 1996) used the Fa-
cial Paralysis Recovery Profile (FPRP) and the Facial Paralysis
Recovery Index (FPRI). (Adour 1971). Hato (Hato 2007) and
Kawaguchi (Kawaguchi 2007) used the Yanagihara scoring system
(Yanagihara 2003), which has a validated system for conversion to
the House-Brackmann scale (House 1985). De Diego (De Diego
1998) presented results using the FPRP and House-Brackmann
scale (House 1985). Engstrom, Sullivan and Yeo (Engström 2008;
Sullivan 2007; Yeo 2008) presented results using theHouse-Brack-
mann scale (House 1985) and Engstrom supplemented this using
the Sunnybrook scale (Ross 1996) to minimise the effects of inter-
rater variability.
Statistical analysis
Six out of the seven studies analysed gave adequate detail: they
clearly stated and then used appropriate statistical tests. OnlyHato
(Hato 2007) scored unclear in this category as the tests used were
not stated.
Differences in baseline between groups
Six out of the seven trials were adequate in this category. De Diego
(De Diego 1998) found a significant difference in rates of hy-
pertension between the two groups: further analysis revealed that
there was no significant difference in trial outcomes as a result.
Kawaguchi (Kawaguchi 2007) reported a significant difference be-
tweenmean age of the treatment groups but further analysis of the
age distribution using the Chi2 test revealed no significant differ-
ence. In the tables in the other studies, no significant differences
between the baseline groups were reported.
Effects of interventions
As all trials reported different intervals and lengths of follow up
lengths, the analyses were performed on data reported at the end of
the study periods of three months (De Diego 1998), four months
(Adour 1996), six months (Hato 2007; Kawaguchi 2007; Yeo
2008) nine months (Sullivan 2007) or 12 months (Engström
2008) after the start of treatment.
Antivirals versus placebo (including antivirals plus
corticosteroids versus placebo plus corticosteroids
and antivirals plus corticosteroids versus no
treatment plus corticosteroids)
This comparison contained six studies (Adour 1996; Engström
2008; Hato 2007; Kawaguchi 2007; Sullivan 2007 and Yeo 2008)
with 1886 participants in total.
The relative rate of incomplete recovery at the end of the study did
not show a significant difference between treatment with antiviral
and treatment with placebo, the RR of incomplete recovery being
0.88 (95% CI 0.65 to 1.18), Analysis 1.1 and Figure 2. Hetero-
geneity was high when the fixed-effect model was used (Chi2 =
11.78, P 0.04, I2 58%), the random-effects model was used to
partially correct for this.
7Antiviral treatment for Bell’s palsy (idiopathic facial paralysis) (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Forest plot of comparison: 1 Antivirals versus placebo or no treatment including comparisons in
which corticosteroids were given to both groups, outcome: 1.1 Incomplete recovery at end of study.
We analysed two subgroups of these trials.Two trials (Engström
2008 and Sullivan 2007) provided data for both these compar-
isons. For the six trials with altogether 1228 participants, which
compared antivirals plus corticosteroids with corticosteroids plus
placebo or no treatment, (Adour 1996; Engström 2008; Hato
2007; Kawaguchi 2007; Sullivan 2007 and Yeo 2008), there was
a significant but slight reduction in the rate of incomplete recov-
ery, RR 0.64 (0.50 to 0.82), favouring the combination of antivi-
rals and corticosteroids over corticosteroids alone. For two trials
(Engström 2008 and Sullivan 2007) which compared antivirals
with placebowithout any complicating additional treatment, there
were 658 participants and the relative rate of incomplete recovery
was again non-significant, RR 1.14 (95% CI 0.80 to 1.62).
One study comparing antivirals and corticosteroids with corticos-
teroids alone (Adour 1996) had data for the outcome motor synk-
inesis or crocodile tears at the end of the study, Analysis 1.2. This
included 99 participants and showed no significant difference be-
tween antivirals and corticosteroids, RR 0.47 (95% CI 0.20 to
1.07)
Adverse events were slightly, but not significantly, less likely with
antiviral treatment than without, Analysis 1.3, RR 1.06 (95%
CI 0.81 to 1.38). This analysis included data from three studies
(Engström 2008; Hato 2007 and Sullivan 2007) and 1544 par-
ticipants.
Antivirals versus corticosteroids
This comparison contained three studies (De Diego 1998;
Engström 2008 and Sullivan 2007) with 768 participants in total.
All three studies gave data for our primary outcome, recovery at
the end of the study. Incomplete recovery was significantly less
common in the participants treated with antivirals than those
treated with corticosteroids. Initial calculations using the fixed-
effect model showed RR 1.96 (95% CI 1.48 to 2.59) but with a
high degree of heterogeneity (Chi2 8.78, P = 0.01, I2 77%). The
analysis was repeated using the random-effects model to partially
correct for this, Analysis 2.1 and Figure 3 , RR 2.82 (95% CI 1.09
to 7.32).
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Figure 3. Forest plot of comparison: 2 Antivirals versus corticosteroids, outcome: 2.1 Incomplete recovery
at end of study.
De Diego (De Diego 1998) alone reported motor synkinesis or
crocodile tears at the end of the study. This analysis contains data
on 101 participants and showed no significant difference between
antiviral and corticosteroid, the RR being only 1.03 (95%CI 0.51
to 2.07), Analysis 2.2, .
Adverse event data were available from the Sullivan 2007 and
Engström 2008 trials. There was no significant difference between
the groups, with RR0.96 (95%CI 0.65 to 1.41) fewer participants
with adverse events in the antivirals than the placebo groups,
Analysis 2.3.
Antivirals plus corticosteroids versus placebo
This comparison contained two studies (Engström 2008; Sullivan
2007) and outcome data on 658 participants.
Incomplete recovery at the end of the study was significantly much
less common with the combined treatment than placebo, Analysis
3.1 and Figure 4, RR 0.56 (95% CI 0.41, 0.76). This analysis had
low heterogeneity (Chi2 0.14, P 0.71, I2 0%).
Figure 4. Forest plot of comparison: 3 Antivirals and corticosteroids versus placebo, outcome: 3.1
Incomplete recovery at end of study.
There were no data available for motor synkinesis or crocodile
tears at the end of the studies.
Adverse events were slightly but not significantly more common
with combined treatment than with placebo, RR 1.15 (95% CI
0.79 to 1.66), Analysis 3.2.
Sensitivity analyses
We investigated the effects of using the comparison antivirals plus
corticosteroids, placebo or no treatment versus corticosteroids,
placebo or no treatment by performing further analyses to investi-
gate whether our conclusions were altered when studies with a fol-
low-up of less than six months were excluded (DeDiego 1998 and
Adour 1996) and when only outcomes reported at greater than six
months were included (Engström 2008 and Sullivan 2007).
Further sensitivity analysis was performed to assess the potential
difference in participant response to aciclovir (Adour 1996, De
Diego 1998,Kawaguchi 2007, Sullivan2007 andYeo 2008) versus
valaciclovir (Engström 2008 and Hato 2007).
Antivirals versus placebo (including antivirals plus
corticosteroids versus placebo or no treatment plus
corticosteroids)
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When Adour 1996 was excluded, the RR of incomplete recovery
was 0.94 (95% CI 0.71 to 1.26, n = 1787). When Adour 1996;
Hato 2007; Kawaguchi 2007 and Yeo 2008 were excluded, the
RR of incomplete recovery was 1.06 (95% CI 0.83 to 1.35, n =
1325). This represents no significant change seen with the removal
of outcomes which reported follow up at six months or less.
When sensitivity analysis was performed to assess the differing
response to aciclovir and valaciclovir, no significant difference was
found. Overall the RR for aciclovir was 0.93 (95% CI 0.45 to
1.90, n = 686) in an analysis which included data from three trials.
Overall the RR for valaciclovir was 0.87 (95% CI 0.66 to 1.14, n
= 1200) in an analysis including data from three trials.
Antivirals versus corticosteroids
When theDeDiego 1998 study was excluded and the analysis was
just performedwithEngström2008 andSullivan 2007, the relative
risk of more benefit with antivirals than with corticosteroids, for
the outcome incomplete recovery at the end of the study, was no
longer significant, RR 2.69 (95% CI 0.73 to 10.01, n = 667).This
study differed in reporting outcome at less than six months and
its exclusion changed the conclusion of the meta-analysis from
“significant” to “non-significant”.
Sensitivity analysis assessing the differing response to aciclovir ver-
sus valaciclovir did not alter the overall conclusion from the meta-
analysis. The respective results were RR aciclovir 4.68 (95% CI
2.25 to 9.74, n = 351) with data from two trials and valaciclovir
RR 1.50 (95% CI 1.11 to 2.03, n = 417) with data from one trial.
Antiviral plus corticosteroid versus placebo
There was no change in the data for this analysis, based on
Engström 2008 and Sullivan 2007. This represents no significant
effect from excluding studies, which report the outcome incom-
plete recovery at the end of the study, which report at less than 6
months.
Sensitivity analysis looking at aciclovir and valaciclovir both re-
sulted in a change to these results. For aciclovir, with data from
one trial, the RR was 0.49 (95% CI 0.23 to 1.05, n = 246) and for
valaciclovir, again with data from one trial, the RR was 0.58 (95%
CI 0.41 to 0.80, n = 412). In both cases, this represents a loss of
significance in the difference between outcomes for antivirals plus
corticosteroids versus placebo.
D I S C U S S I O N
This updated review resolves much of the uncertainty about the
value of herpes simplex antivirals for Bell’s palsy. There was no
evidence of significant benefit from antivirals in comparison with
placebo but they were significantly less efficacious than corticos-
teroids.
When antivirals were compared to placebo, there was little differ-
ence in the recovery of participants receiving either treatment RR
0.88 (95% CI 0.65 to 1.18). This result was influenced by the
Sullivan 2007 trial which suggested that antiviral treatment had a
non-significant detrimental effect on recovery: 27 out of 123 par-
ticipants receiving antivirals had incomplete recovery compared
to 18 out of 122 participants receiving placebo, RR 1.48 (95% CI
0.87 to 2.56). A possible reason is that, although active against the
presumed infective agent, antiviral medication causes increased
local inflammation and exacerbation of symptoms (Jarisch-Herx-
heimer reaction).
When antiviral treatment was compared to corticosteroid treat-
ment, the participants receiving corticosteroid treatment were sig-
nificantlymore likely to recover than those receiving antiviral treat-
ment: that is, there was more incomplete recovery in the antiviral
group RR 2.82 (95%CI 1.09 to 7.32). This analysis displayed sig-
nificant heterogeneity which was not fully corrected by applying
the random-effects model and needs to be interpreted with cau-
tion.
Similarly, the outcome was significantly better in the participants
receiving corticosteroid and antiviral treatment compared with
placebo: that is the RR of incomplete recovery was significantly
less, 0.56 (95% CI 0.41 to 0.76), in those who received combined
treatment.
The RR of incomplete recovery, calculated using the fixed-effects
model, was significantly less 0.75 (95% CI 0.57 to 0.98) with the
combined treatment than with corticosteroids alone which would
suggest a beneficial effect from antivirals but this analysis showed
moderate heterogeneity and should be interpreted with caution.
The source of heterogeneitymay be due to clinical variation for ex-
ample in study participant characteristics, disease severity at base-
line, delay in receiving treatment or type of antiviral agent used.
Equally, variation may be due to methodological considerations
such as method of randomization, the use of blinding, the choice
of outcome assessment measures and recovery cut-off points or the
trial duration. In particular, Hato 2007 and Kawaguchi 2007 had
methodological weaknesses in baseline group assessment, com-
pleteness of follow-up and adequate blinding. Any of these factors
could result in bias and introduce inaccuracy.The heterogeneity
was exacerbated by keeping the inclusion criteria fairly broad: this
maximises data inclusion and therefore power, but results must be
interpreted with this in mind.
Sensitivity analysis of trials with data with less than a six month
end-point showed results similar to those achieved with the whole
group analysis - no significant effect of shortened time of follow
up was detected.
Similarly, sub-group analysis of the relative treatment difference
with different antivirals showed no significant change in the an-
tivirals versus placebo or antivirals versus corticosteroids results.
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In the antivirals plus corticosteroids comparison, the examination
of individual therapy removed the significant difference in incom-
plete outcome. Given this, it is unlikely that different antivirals,
despite the difference in bio-availability (Sullivan 2007), will have
a significant affect on the outcome of incomplete recovery at the
end of the study.
Given that a significant benefit in terms of incomplete recovery at
end of study was derived from the combination of antivirals plus
corticosteroids, this maymerit further investigation. It may be that
the use of prednisolone suppresses the Jarish-Harxheimer reaction
and allows the antiviral treatment to provide some benefit.
There were insufficient data to examine any other variables which
are reported in the studies, such as pain, quality of life and variation
in response due to time to treatment and severity at onset. These
variables can be used as hypothesis generation for future work in
this area.
From theminimal data available for comparison ofmotor synkine-
sis or crocodile tears at the end of the study, the results of two stud-
ies with separate comparisons with a total number of participants
of 200 were not significant. De Diego (De Diego 1998) compared
antivirals with corticosteroids and found fewer episodes of these
outcomes in the corticosteroids group while Adour (Adour 1996)
compared antivirals and corticosteroids with corticosteroids and
found fewer episodes of these outcomes in the antiviral treatment
group. Relatively low participant numbers and a degree of clinical
(different clinical assessment scales used) and methodological het-
erogeneity (different treatment regimes and follow up plans) limit
the interpretation of these data.
No data were available in any of the studies to assess the outcome
’complete paralysis at the end of the study’.
Adverse events data were available in three studies (Engström
2008; Hato 2007 and Sullivan 2007) giving comparison data on
1544 participants. None of the comparisons showed significant
differences in adverse events between either arm . No correlation
with specific treatment could be found within these results.
There has been variation in the clinical end-points chosen as defin-
ing recovery: Engstrom and Sullivan (Engström 2008; Sullivan
2007) useHouse-Brackmann (H-B)Grade 1: Yeo usedH-BGrade
2. The other studies used a variety of different scales which show
more or less equivalence to these. Additional information is at-
tached which give details of the symptoms scales and comparison
where available (Table 1; Table 2; Table 3)
Age at onset, either as an independent predictor of recovery or as
a predictor or treatment response might be an important variable:
Kawaguchi (Kawaguchi 2007) stratified for age and noted a sig-
nificantly lower recovery rate in 40 to 60 year olds compared to
those under 40 years old.
Neither Kawaguchi (Kawaguchi 2007) nor Yeo (Yeo 2008) found
a significant association between time to treatment and final re-
covery status.
There were differences in severity at recruitment: several studies
were based in secondary care (Hato 2007; Kawaguchi 2007 and
Yeo 2008) and so may have included a more severe spectrum of
palsy than those based within primary care. Hato and Kawaguchi
(Hato 2007; Kawaguchi 2007) stratified by severity of disease sta-
tus at onset and found that in cases of complete or severe palsy
the recovery rate for the combination treatment was significantly
greater than that for the corticosteroid only group.
Studies conducted in Asia, North America and Europe, have been
included. It is possible that genetic differences in drug metabolism
or response or even different aetiological processes may account
some of the variation in response which is observed.
The other important consideration which is raised by the primary
outcome result are the health economic issues: a 10 day course of
aciclovir 400 mg five times daily costs GBP 9.28; valaciclovir and
famciclovir equivalent courses cost significantly more; a 10 day
course of prednisolone (two 25 mg tablets daily), costs about GBP
7.14 (BNF 2008). These cost data are specific to the current UK
market and costs vary significantly in other countries (Hernández
2008).
Further work in this area could address the questions raised by
the possible causes of heterogeneity in some of the comparisons
in this review and may be achieved through a combination of epi-
demiological work and further large randomized controlled trials
which collect comparable data for sub-group analysis and meta-
regression.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
High quality evidence from randomized controlled trials of herpes
simplex antivirals for the treatment of Bell’s palsy showed no sig-
nificant benefit from antivirals compared to placebo. High qual-
ity evidence showed significant benefit from the combination of
antivirals and corticosteroids compared with placebo. Moderate
quality evidence showed significantly less benefit from antivirals
than corticosteroids. There was no significant increase in adverse
events from antivirals compared with either placebo or corticos-
teroids.
Implications for research
The results cast doubt on previous hypotheses suggesting herpes
simplex as the cause of Bell’s palsy and research should be aimed
at discovering alternative causes.
More work is needed to assess the likelihood of long term cosmetic
sequelae. Sub-group analysis of existing data and future studies
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should be done to assess the impact of variables such as time from
diagnosis until treatment received, severity of palsy at baseline and
age of patient at presentation on the outcome. Work assessing
softer end-points such as quality of life and perceived disability
should be done to develop better understanding of Bell’s palsy at
the patient level.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adour 1996
Methods Double-blind. Placebo-controlled.
Participants 119 randomized, 99 included in published analysis. Initial diagnosis of idiopathic facial paralysis
in primary care clinics or emergency departments confirmed in facial paralysis research clinic.
Enrolment criteria: paralysis commenced <= 3 days before treatment; all participants over 18 years
of age; good physical health determined by history and physical exam; no contraindication for
steroid or aciclovir treatment; all women of childbearing age had a negative pregnancy test result
Interventions Aciclovir (2000 mg per day for 10 days) and prednisone (1 mg/kg for 5 days tapered to 10 mg/
day for remaining 5 days) or placebo and prednisone (1 mg/kg for 5 days tapered to 10 mg/day for
remaining 5 days)
Outcomes Primary outcome: recovery on facial paralysis recovery index where incomplete recovery is Facial
Paralysis Recovery Profile (FPRP) <=7 at 4 months
Maximal stimulation test +/- electroneurogrpahy at follow up at 2 weeks, 2 months, 3 months and
4 months (if incompete recovery) after paralysis onset
Final outcomes reported at 3months or when recovered or palsy stabilized (notmore clearly defined)
Notes Single centre.
Exclusion criteria: no other medication for idiopathic facial paralysis, urea nitrogen or creatinine >
2x upper limit of normal, liver transaminase > 3x upper limit of normal; haemoglobin level <100
g/L; platelet count < 75 000/mm3; or neutrophil count <1 x 10 to the 6/L
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote “the bottles [of aciclovir and placebo], provided by
Burroughs Wellcome, were randomised in groups of 10”
Allocation concealment? Yes Quote “Each bottle..had a sealed identification label which
was removed intact and kept with the patient’s record”
Blinding of participants? Yes Quote “eligible patients were given identical, unlabeled bot-
tles of 100 capsules that contained either palcebo or aciclovir
(Zovirax), 200 mg”
Patients in each group received identical follow-up
Blinding of assessors? Yes The study is reported as double blind: the method reported
is consistent with being able to achieve this
Incomplete outcome data? Yes The numbers of participants unable to complete the study is
given
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Adour 1996 (Continued)
Selective outcome reporting? No Primary outcome of facial paralysis recovery profile and bi-
lateral facial nerve electrical testing both reported but no data
given on audiometry with stapedial reflex testing
Other sources of bias? No Single centre study
High drop out rate reported - 16.8%
Diagnostic criteria not clearly defined in paper
De Diego 1998
Methods Participants randomly assigned. No further details given.
Participants 113 participants randomized, 101 included in published analysis. Evaluation within first 96 hours.
No contraindications to corticosteroid or aciclovir
Interventions Aciclovir (2400 mg per day for 10 days) or prednisone (1 mg/kg for 10 days then tapered to zero
over next 6 days)
Outcomes Primary outcome: recovery using House-Brackman facial nerve grading scale and facial paralysis
recovery profile (FPRP) (Adour 1971). Where recovery was defined as H-B score <= 2 or FPRP >=
8.
Denervation reportedwithmaximal stimulation test and electromyography in severe cases. Sequelae
and synkinesis recorded separately
Follow up at 1, 3, 6, 12 weeks after first visit. Participants with incomplete recovery at 12 weeks
followed until recovery made or stabilisation of paralysis
Final outcomes reported at 4 months.
Notes Single centre. Both House-Brackman and FPRP scales used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote “Patients were randomly assigned”.
Allocation concealment? No No clear information but unlikely to be true as
no indication of blinding - see below
Blinding of participants? No Presence of blinding not clearly stated but un-
likely to be the case as groups receive different
treatment regimens (corticosteroids once daily or
aciclovir three times daily) with no clear method
for concealing this difference
Blinding of assessors? Unclear This is not mentioned in the study.
Incomplete outcome data? Yes Number lost to follow up reported.
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De Diego 1998 (Continued)
Selective outcome reporting? Yes All desired outcomes reported.
Other sources of bias? No Single centre study.
Engström 2008
Methods Participants randomized by computerised mechanism in a two-stage process into four treatment
groups.: valaciclovir with prednisolone (AS), valaciclovir with placebo (AO), placebo with pred-
nisolone (OS) or double placebo (OO)
Participants 829 participants randomized within 72 hours of facial palsy onset. No contraindications to corti-
costeroids or antivirals use
Interventions Participants allocated into one of four treatment groups as described above and received a combi-
nation of valaciclovir 1000 mg three times daily for 7 days +/- prednisolone 60 mg daily for 5 days
Outcomes Primary outcome: recovery of facial function, as assessed at all visits with the Sunnybrook Scale
and the House-Brackmann Scale. Where complete recovery was taken as Sunnybrook scale 100 or
H-B grade 1
Degree of pain as recorded during the first 2 months and adverse events were recorded for the first
month. Borrelia burgdorferi serology was measured at baseline and 2 months. Frequency of severe
pain, synkinesis, facial spasm and residual facial symptoms at 12 months is recorded
Follow up at 2 weeks, 1 month, 2 months 3 months, 6 months and 12 months after randomization
according to recovery
Final outcomes reported at 12 months.
Notes Multi-centre. Sunnybrook and House-Brackman scales used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote “..randomization code was developed by
GlaxoWellcomeGmBH,with a computer num-
ber generator to select random permuted blocks
of eight”
Allocation concealment? Yes Randomization code double-blind and held by
third party - medication dispensed in identical
containers according to allocation concealment
Blinding of participants? Yes Study drugs issued in identical containers. All
participants blinded to treatment group until
study completion
Blinding of assessors? Yes All study personnel and data analysts blinded to
treatment group until study completion
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Engström 2008 (Continued)
Incomplete outcome data? Yes Numbers lost to follow up and reasons for this
given.
Selective outcome reporting? Yes Secondary outcomes listed but not reported:
all primary outcomes reported. Other outcomes
will be reported in another paper due to space
constrictions
Other sources of bias? Yes No other potential sources of bias identified.
Hato 2007
Methods Random allocation to 2 groups to receive either valaciclovir and prednisolone (VP) or placebo and
prednisolone (PP). Using the ’envelope’ method
Participants 296 participants randomized; 152 participants to VP, 144 participants to PP. All participants
commenced treatment within 7 days of onset of palsy. All participants over 15 years and had no
contraindications to antivirals or corticosteroids. 221 patients were included in the final analysis
Interventions Randomized to receive prednisolone 60 mg for 5 days, 30 mg for 3 days and 10 mg for 2 days +/-
valaciclovir 1000 mg/ day for 5 days. All participants received mecobalamin 1500 micrograms per
day following corticosteroids for 6 months or until complete recovery
Outcomes Primary outcome full recovery based on a score of >= 36 on the Yanagihara scale
Follow up at 1,3 and 6 months after commencing treatment.
Final outcomes reported at 6 months.
Notes Multi-centre: 6 academic tertiary referral centres.Measurements using Yanagihara scale - conversion
scale to House-Brackmann scale included in paper
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote “the patients were randomly divided into
two groups using the envelope method”
Allocation concealment? No Allocation was only concealed until intervention
assigned.
Blinding of participants? No Inadequate. Participants blinded to treatment
but different treatments with different frequen-
cies mean true blinding was not achieved
Blinding of assessors? No Inadequate - not done. Assessors not blinded to
treatment.
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Hato 2007 (Continued)
Incomplete outcome data? Yes Participants who did not complete the study
have frequency and reason for drop out docu-
mented
Selective outcome reporting? Yes Main outcome measures all reported.
Other sources of bias? No High drop out rate reported - 19%.
Statistical tests employed not clearly stated.
Kawaguchi 2007
Methods Random allocation to receive either prednisolone or prednisolone and valaciclovir. Using the ’en-
velope’ method
Participants 150 participants: 66 prednisolone, 84 prednisolone and valaciclovir. All participants received treat-
ment within 7 days from onset of palsy. All participants aged 15 or older and had no contraindi-
cations to corticosteroids or antivirals
Interventions Participants received 20 mg three times daily for days 1 to 5, then 10 mg three times daily days 6
to 8, then 10 mg daily days 9 and 10 +/- valaciclovir 500 mg twice a day for 5 days
Outcomes Facial movement and recovery measured using the Yanagihara scale where compete recovery was
taken as a score of >= 36
Virological examination for presence of antiHSV and VZV antibodies and detection of HSV and
VZV reactivation. Frequency of incomplete recovery at end of study and adverse events recorded
but not published - information obtained from author (by PL)
Follow up for 6 months at 1 and 2 weeks after treatment and then at 1, 2, 3, 4, 5 and 6 months
after treatment
Final outcomes reported at 6 months.
Notes Multi-centre: 12 university hospitals. Yanagihara rating scale
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Sequence generation using envelope method.
Allocation concealment? No Not used - when entered in the trial, the allo-
cation envelope contains the name of the treat-
ment group
Blinding of participants? No Not done.
Blinding of assessors? No Not done.
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Kawaguchi 2007 (Continued)
Incomplete outcome data? Yes Numbers of participants who did not complete
clearly documented
Selective outcome reporting? Yes All primary outcomes reported.
Other sources of bias? Yes No other potential sources of bias identified.
Sullivan 2007
Methods Double-blind, placebo-controlled randomized, factorial trial. Participants allocated to one of four
treatment groups to receive either aciclovir, prednisolone, both agents or placebo
Participants 551 participants randomized and 496 included in final outcomes assessment. Referred for assess-
ment and treatment within 72 hours of paralysis onset. All participants aged 16 or older and no
contraindications to corticosteroids or antivirals
Interventions Participants received prednisolone 25 mg twice daily for 10 days or aciclovir 400 mg five times
daily for 10 days, both or neither depending upon allocation
Outcomes Primary outcome measure was recovery rated on House-Brackmann scale where recovery was a
score of H-B grade 1
Secondary outcomes included health-related quality of life, Health Utilities Index Mark 3, facial
appearance (Derriford appearance scale) pain and adverse outcomes. Frequency of incomplete
recovery at end of study was recorded
Follow up at 3 and 9 months.
Final outcomes reported at 9 months.
Notes Multi-centre: 17 hospitals. House-Brackmann Scale.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote “...patient was randomly assigned to a
study group by an independent, secure, auto-
mated telephone randomization service..”
Allocation concealment? Yes All parties blinded to allocation.
Blinding of participants? Yes Participants not receiving active drug given
placebo. All administered medication identical
and in identical containers
Blinding of assessors? Yes Assessors blinded to treatment group.
Incomplete outcome data? Yes All participants who were unable to complete are
documented - both frequency and reason
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Sullivan 2007 (Continued)
Selective outcome reporting? Yes All planned outcome measures reported.
Other sources of bias? Yes No other potential sources of bias identified.
Yeo 2008
Methods Randomized and double-blind. Two-arm design.
Participants Included 91 participants with other causes of facial palsy excluded. Nomaximum period after onset
stated but actual time to treatment recorded
Interventions Randomized to receive either aciclovir and prednisolone or corticosteroids alone. aciclovir given
at a dose of 2400 mg/day for 5 days. Prednisolone given as 1 mg/kg/day for 5 days then tapered
on days 6 to 10. All participants admitted to hospital and received physical therapy and plasma
volume expanders as adjuncts
Outcomes Primary outcome was recovery on House-Brackmann (H-B) scale where recovery was taken as H-
B <=2
Sub-group analysis of early versus delayed treatment.
Follow up at 2 and 6 months.
Final outcomes reported at 6 months.
Notes Single centre. All participants admitted. Biased towards severe palsy. House-Brackmann Scale
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear States randomized in study title but no descrip-
tion of this in the article
Allocation concealment? Unclear No clear statement of this in the study.
Blinding of participants? Unclear States double-blind in study title but no descrip-
tion of methods employed for this in text
Blinding of assessors? Unclear States double-blind in study title but no descrip-
tion of methods employed for this in text
Incomplete outcome data? Unclear Incomplete follow-up data is not mentioned in
the study.
Selective outcome reporting? Yes Stated primary outcome measure reported.
Other sources of bias? No Single centre study.
All participants admitted.
Biased towards cases of severe palsy.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahangar 2006 No random allocation to treatment groups.
Antunes 2000 Not enough information in original paper. Author contacted by Dr D Allen but no response received
Axelsson 2003 Use of a historical control group.
Chen 2005 Follow up data for four weeks from palsy onset only.
Hato 2003 Retrospective analysis of treatment.
Hultcrantz 2005 No random allocation to treatment groups.
Ibarrondo 1999 Retrospective study. One hundred participants collected between 1983 and 1989 received corticotherapy. One
hundred participants treated after 1989 received aciclovir
P de Aquino 2001 Methodology not clear from original paper. Authors contacted by D Allen but no response. Confirmed by
contacting D Allen in 2008 (PL)
Ramos Macias 1992 Inadequate allocation concealment. No information reported about methods of randomization; the diagnostic
criteria used; the length of follow-up or number of participants lost to follow-up
Roy 2005 Inadequate information: abstract only published in journal supplement and not traced as a full publication
Zhou 1999 Prospective study. Sixty-nine participants with Bell’s palsy followed up for 2 weeks only. Not double-blind
and allocation concealment not described. Used own scale for palsy grading, outcome measures not met. Did
report adverse events. Four aciclovir treatment participants had gastric malaise
Characteristics of studies awaiting assessment [ordered by study ID]
Inanli 2001
Methods Prospective, controlled, randomized study
Participants 42 participants
Interventions 20 treated with aciclovir plus prednisone, 22 treated with prednisone alone
Outcomes Neural regeneration
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticos-
teroids or no treatment plus corticosteroids)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incomplete recovery at end of
study
6 1886 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.65, 1.18]
1.1 Antivirals plus
corticosteroids versus placebo
plus corticosteroids or no
treatment plus corticosteroids
6 1228 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.48, 1.05]
1.2 Antivirals versus placebo 2 658 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.80, 1.62]
2 Motor synkinesis or crocodile
tears
1 99 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.20, 1.07]
3 Adverse Events 3 1544 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.81, 1.38]
Comparison 2. Antivirals versus corticosteroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incomplete recovery at end of
study
3 768 Risk Ratio (M-H, Random, 95% CI) 2.82 [1.09, 7.32]
2 Motor synkinesis at end of study 1 101 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.51, 2.07]
3 Adverse Events 2 667 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.65, 1.41]
Comparison 3. Antivirals plus corticosteroids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incomplete recovery at end of
study
2 658 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.41, 0.76]
2 Adverse Effects 2 658 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.79, 1.66]
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Analysis 1.1. Comparison 1 Antivirals versus placebo (including antivirals plus corticosteroids versus
placebo plus corticosteroids or no treatment plus corticosteroids), Outcome 1 Incomplete recovery at end of
study.
Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)
Comparison: 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids)
Outcome: 1 Incomplete recovery at end of study
Study or subgroup AV plus CS or placebo CS or placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids
Adour 1996 7/53 13/46 9.3 % 0.47 [ 0.20, 1.07 ]
Engstrm 2008 42/206 50/210 22.7 % 0.86 [ 0.60, 1.23 ]
Hato 2007 4/114 11/107 5.8 % 0.34 [ 0.11, 1.04 ]
Kawaguchi 2007 8/84 9/66 8.3 % 0.70 [ 0.29, 1.71 ]
Sullivan 2007 9/124 5/127 6.3 % 1.84 [ 0.64, 5.35 ]
Yeo 2008 3/44 7/47 4.6 % 0.46 [ 0.13, 1.66 ]
Subtotal (95% CI) 625 603 56.9 % 0.71 [ 0.48, 1.05 ]
Total events: 73 (AV plus CS or placebo), 95 (CS or placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 7.02, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 1.71 (P = 0.087)
2 Antivirals versus placebo
Engstrm 2008 74/207 73/206 27.2 % 1.01 [ 0.78, 1.31 ]
Sullivan 2007 27/123 18/122 16.0 % 1.49 [ 0.87, 2.56 ]
Subtotal (95% CI) 330 328 43.1 % 1.14 [ 0.80, 1.62 ]
Total events: 101 (AV plus CS or placebo), 91 (CS or placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.63, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 955 931 100.0 % 0.88 [ 0.65, 1.18 ]
Total events: 174 (AV plus CS or placebo), 186 (CS or placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 12.40, df = 7 (P = 0.09); I2 =44%
Test for overall effect: Z = 0.86 (P = 0.39)
0.2 0.5 1 2 5
Favours antivirals Favours placebo
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Analysis 1.2. Comparison 1 Antivirals versus placebo (including antivirals plus corticosteroids versus
placebo plus corticosteroids or no treatment plus corticosteroids), Outcome 2 Motor synkinesis or crocodile
tears.
Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)
Comparison: 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids)
Outcome: 2 Motor synkinesis or crocodile tears
Study or subgroup AV plus CS or placebo CS or placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adour 1996 7/53 13/46 100.0 % 0.47 [ 0.20, 1.07 ]
Total (95% CI) 53 46 100.0 % 0.47 [ 0.20, 1.07 ]
Total events: 7 (AV plus CS or placebo), 13 (CS or placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antivirals Favours placebo
Analysis 1.3. Comparison 1 Antivirals versus placebo (including antivirals plus corticosteroids versus
placebo plus corticosteroids or no treatment plus corticosteroids), Outcome 3 Adverse Events.
Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)
Comparison: 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids)
Outcome: 3 Adverse Events
Study or subgroup AV plus CS or placebo CS or placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Engstrm 2008 50/413 46/416 50.0 % 1.09 [ 0.75, 1.60 ]
Hato 2007 3/114 2/105 2.3 % 1.38 [ 0.24, 8.11 ]
Sullivan 2007 44/247 44/249 47.8 % 1.01 [ 0.69, 1.47 ]
Total (95% CI) 774 770 100.0 % 1.06 [ 0.81, 1.38 ]
Total events: 97 (AV plus CS or placebo), 92 (CS or placebo)
Heterogeneity: Chi2 = 0.18, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours antivirals Favours placebo
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Analysis 2.1. Comparison 2 Antivirals versus corticosteroids, Outcome 1 Incomplete recovery at end of
study.
Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)
Comparison: 2 Antivirals versus corticosteroids
Outcome: 1 Incomplete recovery at end of study
Study or subgroup AV CS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
De Diego 1998 12/54 3/47 26.0 % 3.48 [ 1.05, 11.60 ]
Engstrm 2008 74/207 50/210 42.6 % 1.50 [ 1.11, 2.03 ]
Sullivan 2007 27/123 5/127 31.4 % 5.58 [ 2.22, 14.01 ]
Total (95% CI) 384 384 100.0 % 2.82 [ 1.09, 7.32 ]
Total events: 113 (AV), 58 (CS)
Heterogeneity: Tau2 = 0.53; Chi2 = 8.78, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 2.13 (P = 0.033)
0.1 0.2 0.5 1 2 5 10
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Analysis 2.2. Comparison 2 Antivirals versus corticosteroids, Outcome 2 Motor synkinesis at end of study.
Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)
Comparison: 2 Antivirals versus corticosteroids
Outcome: 2 Motor synkinesis at end of study
Study or subgroup AV CS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Diego 1998 13/54 11/47 100.0 % 1.03 [ 0.51, 2.07 ]
Total (95% CI) 54 47 100.0 % 1.03 [ 0.51, 2.07 ]
Total events: 13 (AV), 11 (CS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
0.2 0.5 1 2 5
Favours antivirals Favours corticosteroids
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Analysis 2.3. Comparison 2 Antivirals versus corticosteroids, Outcome 3 Adverse Events.
Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)
Comparison: 2 Antivirals versus corticosteroids
Outcome: 3 Adverse Events
Study or subgroup AV CS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Engstrm 2008 23/207 21/210 46.9 % 1.11 [ 0.63, 1.94 ]
Sullivan 2007 19/123 24/127 53.1 % 0.82 [ 0.47, 1.41 ]
Total (95% CI) 330 337 100.0 % 0.96 [ 0.65, 1.41 ]
Total events: 42 (AV), 45 (CS)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours antivirals Favours corticosteroids
Analysis 3.1. Comparison 3 Antivirals plus corticosteroids versus placebo, Outcome 1 Incomplete recovery
at end of study.
Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)
Comparison: 3 Antivirals plus corticosteroids versus placebo
Outcome: 1 Incomplete recovery at end of study
Study or subgroup AV plus CS placebo/ no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Engstrm 2008 42/206 73/206 80.1 % 0.58 [ 0.41, 0.80 ]
Sullivan 2007 9/124 18/122 19.9 % 0.49 [ 0.23, 1.05 ]
Total (95% CI) 330 328 100.0 % 0.56 [ 0.41, 0.76 ]
Total events: 51 (AV plus CS), 91 (placebo/ no treatment)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.79 (P = 0.00015)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
antivirals plus steroid placebo
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Analysis 3.2. Comparison 3 Antivirals plus corticosteroids versus placebo, Outcome 2 Adverse Effects.
Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)
Comparison: 3 Antivirals plus corticosteroids versus placebo
Outcome: 2 Adverse Effects
Study or subgroup AV plus CS placebo/ no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Engstrm 2008 27/206 25/206 55.4 % 1.08 [ 0.65, 1.80 ]
Sullivan 2007 25/124 20/122 44.6 % 1.23 [ 0.72, 2.09 ]
Total (95% CI) 330 328 100.0 % 1.15 [ 0.79, 1.66 ]
Total events: 52 (AV plus CS), 45 (placebo/ no treatment)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
antiviral plus steroid placebo
A D D I T I O N A L T A B L E S
Table 1. House-Brackmann Scale
Grade Description
I Normal
II Mild dysfunction; slight weakness noticeable only on close inspection; may have slight synkinesis
III Moderate dysfunction; obvious but not disfiguring difference between the two sides; noticeable but not severe synkinesis
IV Moderately severe dysfunction; obvious weakness and/or disfiguring asymmetry
V Only barely perceptible motion
VI No movement
House JW. Facial nerve grading systems. Laryngoscope 1983; 93: 1056-69.
House JW, Brackmann DE. Facial nerve grading system. Otolaryngology, Head and Neck Surgery 1985; 93: 146-7.
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Table 2. Yanighara scale
Mode Degree of paralysis
4
normal
3
slight
2
moderate
1
severe
0
total
At rest
Wrinkle forehead
Blink
Normal closure of
eye
Forced closure of
eye
Closure of eye on in-
volved side
Wrinkle nose
Whistle
Grin
Depress lower lip/
blow out cheek
Ten separate categories of function, each scored 0 (total paralysis) to 4 (normal), then summed, giving a total score 0 (total paralysis)
to 4 (normal), then summed, giving a total score from 0 (total paralysis) to 40 (normal function).
Yanighara N. Grading of facial palsy. Proc 3rd International Symposium on Facial Nerve Surgery, Zurich 1976. In Fish U., ed.Facial
Nerve Surgery. Amstelveen, The Netherlands: Kugler Medical Publications 1977: 533-5.
Table 3. Sunnybrook Scale
Facial Grading System
Resting Symmetry Symmetry of Voluntary Move-
ment
Synkinesis
Compared to Normal Side Degree of muscle EXCURSION
compared to normal side
Degree of INVOLUNTARY
MUSCLE CONTRACTION as-
sociated with each expression
Eye STANDARD EXPRESSIONS
Forehead Wrinkle
STANDARD EXPRESSIONS
Forehead Wrinkle
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Table 3. Sunnybrook Scale (Continued)
Gentle eye closure
Open mouth smile
Snarl
Lip Pucker
Score each out of 5, where 5 is nor-
mal and 1 is gross asymmetry/no
movement)
Gentle eye closure
Open mouth smile
Snarl
Lip Pucker
Score each facial movement listed
under standard expressions on a
scale 0-3 where 0 is no asymmetry
and 3 is severe asymmetry
Normal = 0
Narrow = 1
Wide =1
Eyelid surgery = 1
Cheek
Normal = 0
Absent = 2
Less pronounced = 1
More pronounced =1
Mouth
Normal = 0
Corner drooped =1
Corner pulled up/out = 1
TOTAL TOTAL TOTAL
Resting Symmetry Score x 5 Voluntary Movement Score
Total x 4
Synkinesis Score
Voluntary Movement Score - Resting Symmetry Score - Synkinesis Score = Composite Score
Weighted regional evaluation using five separate expressions. Composite score from 0 (total paralysis) to 100 (normal function). See
Ross et al (1996).
Ross BG, Fradet G and Nedzelski JM. Development of a sensitive clinical facial grading system. Otolaryngol Head Neck Surg 1996;
114: 380-386.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1 randomized controlled trial.pt.
2 controlled clinical trial.pt.
3 randomized controlled trials/
4 random allocation/
5 double-blind method/
6 single-blind method/
7 or/1-6
8 animals/ not humans/
9 7 not 8
10 clinical trial.pt.
11 exp clinical trial/
12 (clin$ adj25 trial$).ti,ab.
13 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).ti,ab.
14 placebos/
15 placebo$.ti,ab.
16 random$.ti,ab.
17 research design/
18 or/10-17
19 18 not 8
20 19 not 9
21 comparative study/
22 exp evaluation studies/
23 follow up studies/
24 prospective studies/
25 (control$ or prospectiv$ or volunteer$).ti,ab.
26 or/21-25
27 26 not 8
28 27 not (9 or 20)
29 9 or 20 or 28
30 exp Facial Nerve Diseases/
31 bell palsy/
32 facial paralysis/ or hemifacial spasm/
33 ((Bell$ or facial$ or hemifacial$ or unilateral$ or nerve$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).mp. (21743)
34 30 or 31 or 32
35 34 or 33
36 Acyclovir/
37 exp Acyclovir/
38 (aciclovir$ or valaciclovir$).mp.
39 (acyclovir$ or valacyclovir$).mp.
40 36 or 37 or 38 or 39
41 29 and 35 and 40
42 limit 41 to ed=20071015-20081210
43 from 42 keep 1-5
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Appendix 2. EMBASE search strategy
1 Randomized Controlled Trial/
2 Clinical Trial/
3 Multicenter Study/
4 Controlled Study/
5 Crossover Procedure/
6 Double Blind Procedure/
7 Single Blind Procedure/
8 exp RANDOMIZATION/
9 Major Clinical Study/
10 PLACEBO/
11 Meta Analysis/
12 phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
13 (clin$ adj25 trial$).tw.
14 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw.
15 placebo$.tw.
16 random$.tw.
17 control$.tw.
18 (meta?analys$ or systematic review$).tw.
19 (cross?over or factorial or sham? or dummy).tw.
20 ABAB design$.tw.
21 or/1-20
22 human/
23 nonhuman/
24 22 or 23
25 21 not 24
26 21 and 22
27 25 or 26
28 exp Nerve Paralysis/
29 bell palsy/
30 facial nerve paralysis/ or hemifacial spasm/
31 ((Bell$ or facial$ or hemifacial$ or unilateral$ or cranial$ or nerve$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).mp.
32 or/28-31
33 ACICLOVIR/
34 (aciclovir$ or valaciclovir$).mp.
35 (acyclovir$ or valacyclovir$).mp.
36 33 or 34 or 35
37 27 and 32 and 36
38 limit 37 to em=200742-200850
39 from 38 keep 1-31
Appendix 3. LILACS search strategy
Facial Nerve Diseases or bell palsy or facial paralysis hemifacial spasm or ((Bell or bells or facial or hemifacial or unilateral or nerve or
cranial) and (palsy or palsies or paralysis or paresi$ or spasm or spasms)) [Words] and Acyclovir or ganiclovir or aciclovir or valaciclovir
or acyclovir or valacyclovir [Words] and ((Pt randomized controlled trial OR Pt controlled clinical trial ORMh randomized controlled
trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) AND NOT (Ct animals AND NOT
(Ct humans and Ct animals)) OR (Pt clinical trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw
estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR
Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw
placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design)
AND NOT (Ct animals AND NOT (Ct humans and Ct animals)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up
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studies ORMh prospective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) ANDNOT (Ct animals
AND NOT (Ct humans and Ct animals))) [Words]
WH A T ’ S N E W
Last assessed as up-to-date: 24 February 2009.
Date Event Description
12 May 2010 Amended Correction to reference
H I S T O R Y
Protocol first published: Issue 3, 1999
Review first published: Issue 2, 2001
Date Event Description
10 November 2009 Amended Correction of minor error in Discussion.
25 February 2009 New citation required and conclusions have changed This is a substantive update to the previous edition of
the review with a new review team. Five new studies
added to the analysis with changes made to Results
and Discussion sections as necessary
5 February 2009 New search has been performed Substantive update to previous edition of review.
Abstract and background information re-written.
Modification of outcomes: all data from trials, what-
ever the trial length as opposed to 6 month outcomes.
Five new studies added to the analysis with necessary
changes made to Results and Discussion sections. One
study removed from the previous review as no data
contributed andnone forthcoming toprevious authors
when approached
1 November 2007 Amended Two trials, one with 551 participants comparing pred-
nisolone with acyclovir with both andwith neither, an-
other with 221 participants comparing prednisolone
and valacyclovir with prednisolone and placebo have
just been published and will be included in an update
of this review
1 March 2004 New citation required and conclusions have changed Substantive amendment
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(Continued)
1 January 2004 New search has been performed The review was updated in January 2004. Searches
were updated as follows: Neuromuscular Disease
Group Trials Register (searched April 2003), MED-
LINE (searched January 1966 to April 2003), EM-
BASE (searched January 1980 to April 2003), and
LILACS (searched January 1982 to April 2003)
C O N T R I B U T I O N S O F A U T H O R S
All authors contributed to the review and data extraction process. Dr F Daly wrote the first draft of the report with all clinical inputs
from Professor F Sullivan and Dr P Lockhart. Dr P Lockhart incorporated the work into the existing review and was responsible for
risk of bias assessment, data analysis and use of the RevMan software.
D E C L A R A T I O N S O F I N T E R E S T
Dr F Daly and Professor F Sullivan are named authors on one of the included studies (Sullivan 2007).
S O U R C E S O F S U P P O R T
Internal sources
• University of Dundee, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There are several differences between the published review protocol and this version of the review. These mainly reflect the changes
over time to the treatment options and Cochrane methodology. The search for studies now includes treatment with valaciclovir and
famciclovir, either alone or in combination with any other therapy, to reflect the treatment options now available for Bell’s palsy. The
methodological assessment has been undertaken according to the latest Cochrane guidance, detailed in the Cochrane Handbook for
Systematic Reviews of Interventions Chapter 8. Criteria for judging study quality are sequence generation, allocation concealment,
blinding of participants and outcome assessors, selective outcome reporting and other sources of bias. The criteria are assessed as ’Yes’,
indicating a low likelihood of bias, ’No’, indicating a high likelihood of bias or ’Unclear’ where information is not sufficient to make
a judgement. Other sources of bias which are considered includes diagnostic criteria, outcome criteria, baseline differences between
groups and completeness of follow up. All five authors were given a selection of papers to read, review for quality and extract data from.
The work was distributed so that each paper was reviewed by at least two authors. PL performed the final risk of bias quality assessment
procedure which was independently reviewed by FS and FD.
We have focused this search on immunocompetent patients, which was not stipulated in the original protocol. This has been done as
treatment protocols for immunocompromised individuals and treatment response may differ significantly from other individuals and,
as such, cannot be fully explored in this analysis.
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We have widened the outcome criteria to include outcomes at the end of the study as opposed to one year or six months after treatment.
This is to allow inclusion of a maximal number of published studies. It is understood that this may introduce significant heterogeneity
to the results and a sensitivity analysis looking at outcomes in participants in studies reporting at 12 weeks or less and six months or
less was included in order to assess the influence this had on the robustness of published results.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acyclovir [analogs&derivatives; ∗ therapeutic use]; Anti-InflammatoryAgents [therapeutic use]; Antiviral Agents [∗ therapeutic use]; Bell
Palsy [∗drug therapy; virology]; Drug Therapy, Combination [methods]; Herpes Simplex [complications; ∗drug therapy]; Prednisolone
[therapeutic use]; Randomized Controlled Trials as Topic; Valine [analogs & derivatives; therapeutic use]
MeSH check words
Humans
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